Three vs six months treatment for CRC in the adjuvant setting: Experts Knowledge Share

Prof. Dr Dominik Modest studied medicine at the Charité in Berlin, Germany and at the University of Bern, Switzerland. Currently, after 10 years at the LMU in Munich, Germany, he is a physician at the Charité Universitaetsmedizin Berlin, Germany. His research activities focus on metastatic colorectal cancer and include the concept and coordination of trials for the FIRE study group and the Arbeitsgemeinschaft Internistische Onkologie (AIO). Prof. Dr Modest also coordinates the translational research components of these trials, aiming to identify prognostic and predictive biomarkers of metastatic colorectal cancer. His research has been published in several papers in scientific journals. In 2015, he received a postdoctoral qualification on factors for personalisation of metastatic colorectal cancer therapy and a full professorship in 2020.  Prof. Dr Modest is an active member of several national and international cancer associations and served as spokesman for the Young Medical Oncologists of the AIO until 2014.

Dr Loredana Vecchione was awarded her medical degree in 2004, her degree as specialist in Medical Oncology in 2008 and her Ph.D from the Second University of Naples in 2012. She performed the last two years of her Ph.D program in Leuven, in Professor Tejpar’s group. After achieving the ESMO fellowship for Translational Research in 2012, she joined Professor Bernards’ group at the Netherlands Cancer Institute where she has been focusing on identifying vulnerabilities of BRAF-like CC. She recently joined the group of Prof Keilholz at the Comprehensive Cancer Center at the Charite in Berlin where she is investigating mechanisms of resistance to conventional treatments in BRAF-like CC and the role of certain genes in some of the CRC subtypes. Dr Vecchione is an active member of ESMO. She is involved in the assignment of educational hours (ESMO CME points) to proposed activities. She has been Section Editor of Current Colorectal Cancer Reports since 2014 and Section Editor of Current Oncology Reports since 2015.